Delving into the Latest Updates on Supergene Co., Ltd. with Synapse

概览

排名前五的药物类型	数量

酶	1

排名前五的靶点	数量

PLG(纤溶酶原)	1

关联

1

项与 Supergene Co., Ltd. 相关的药物

Recombinant staphylokinase(Supergene Co. Ltd.)

靶点

PLG

作用机制

PLG刺激剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

7

项与 Supergene Co., Ltd. 相关的临床试验

NCT06362746

/ Recruiting临床3期

Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of a Single Bolus Administration of Non-immunogenic Recombinant Staphylokinase in Patients With Intermediate High-risk Pulmonary Embolism (FORPE-2)

Objective: to evaluate the efficacy and safety of the non-immunogenic recombinant staphylokinase with its single bolus administration in comparison with placebo in normotensive patients with intermediate high-risk pulmonary embolism (PE)

开始日期2024-05-23

申办/合作机构

Supergene Co., Ltd.

NCT05372718

/ Recruiting临床3期

Multicenter, Open-label, Randomized Clinical Trial of Efficacy and Safety of the Thrombolysis With Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) in Patients With ALI vs Surgery

Objective: to evaluate the efficacy and safety of intra-arterial intrathrombus administration of the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with acute limb ischemia (ALI) vs surgery.

开始日期2022-12-26

申办/合作机构

Supergene Co., Ltd.

NCT05135546

/ Terminated临床2/3期

Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial

Objective: to evaluate the tolerability, safety and efficacy of inhaled usage of the Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) vs placebo in patients with COVID-19.

开始日期2021-12-27

申办/合作机构

Supergene Co., Ltd.

[+1]

100 项与 Supergene Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Supergene Co., Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Supergene Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Supergene Co., Ltd. 相关的转化医学

登录后查看更多信息